Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?

AbbVie is highlighted as a dividend growth standout with a forward yield of around 3% and a forward P/E near 16x, supported by nearly 12% annualized dividend growth since its 2013 spinoff. Adjusted earnings are expected to rise from about $10 per share in 2025 to $14.24 in 2026 and $16.23 in 2027, while the payout ratio remains a sustainable 42%. The article is broadly constructive on AbbVie’s fundamentals and dividend durability, but it is largely commentary rather than new company-specific news.

Analysis

ABBV screens less like a classic defensive pharma and more like a self-funding capital-return compounder with an earnings bridge already visible to 2027. The key second-order effect is that as the portfolio shifts away from Humira concentration, the market should gradually re-rate ABBV from “patent-cliff recovery” to “durable cash-flow annuity,” which matters because dividend stocks with visible low-double-digit EPS growth typically command a premium multiple versus ex-growth pharma peers.

The relative setup versus PFE is more interesting than the headline valuation spread suggests. PFE’s lower multiple reflects not just skepticism, but a balance-sheet and pipeline overhang that reduces its ability to defend capital returns through the cycle; ABBV’s stronger payout coverage gives it room to keep hiking the dividend without crowding out internal investment. That creates a subtle winner in the healthcare supply chain too: contract manufacturers and specialty-biologics adjacent suppliers may benefit more from ABBV’s growing immunology franchise than from legacy small-molecule names facing cliff risk.

The main risk is not a dividend cut over the next 12 months; it is multiple compression if growth decelerates faster than expected or if immunology competition arrives earlier than consensus. Because ABBV is now owned partly as a yield proxy, it can trade like a bond substitute if real rates back up, so the setup is more vulnerable to rate shocks than the operating story implies. The consensus may be underweighting how much of the upside is already in the earnings trajectory, making the stock a better buy on 5-10% drawdowns than at current levels.

From a timing standpoint, this is a months-to-years thesis, not a days trade. In the near term, the stock should be supported by estimate revisions and buyback/dividend demand, but upside will likely be capped unless management can signal a cleaner path to mid-teens EPS growth beyond 2027. The cleanest expression is relative: ABBV as a high-quality long versus lower-quality pharma yield names, rather than an absolute long in a rising-rate tape.

Key Decisions for Investors

• Long ABBV vs short PFE for a 6-12 month pair: ABBV has better earnings visibility and payout durability, while PFE remains exposed to declining forward estimates; target 10-15% relative outperformance with less index beta.
• Buy ABBV only on 5-10% pullbacks or after a rate-driven selloff: use weakness to get paid for the dividend while improving entry into a 2-3 year compounding story; avoid chasing after strong runs because the multiple is already reflecting some recovery.
• If rates resume moving higher, hedge ABBV with a short-duration healthcare basket or put spreads: ABBV can behave like a bond proxy in risk-off, rate-up tape, so the main risk is multiple compression rather than fundamentals.
• Consider long ABBV / long XLV, short PFE as a quality spread within healthcare: this isolates the market’s preference for visible cash-flow growth over low-multiple but lower-visibility pharma names.
• For income-focused accounts, hold ABBV as a core position but cap sizing at a level that tolerates 15-20% drawdown from valuation compression; the reward is steady dividend growth, not explosive price appreciation.